Expression of HuR, COX-2, and survivin in lung cancers; Cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas

Modern Pathology

Volumn 24, Issue 10, 2011, Pages 1336-1347

  Kim, Gou Young ^a   Lim, Sung Jig ^a   Kim, Youn Wha ^b  

^a Kyung Hee University College of Medicine   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

Author keywords

apoptosis regulatory proteins; cyclooxygenase 2; immunohistochemistry; lung neoplasms; nuclear export signals; RNA binding proteins

Indexed keywords

CYCLOOXYGENASE 2; HU ANTIGEN R; NUCLEIC ACID BINDING PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; CYCLOOXYGENASE 2; CYTOPLASM; FEMALE; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PNEUMONECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053574183     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.90     Document Type: Article

References (46)

1. Brennan CM, Steitz JA. HuR and mRNA stability. Cell Mol Life Sci 2001;58:266-277. (Pubitemid 32217358)
2. Gallouzi IE, Steitz JA. Delineation of mRNA export pathways by the use of cell-permeable peptides. Science 2001;294:1895-1901. (Pubitemid 33101580)
3. Dixon DA, Tolley ND, King PH, et al. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 2001;108:1657-1665. (Pubitemid 33144876)
4. Erkinheimo TL, Lassus H, Sivula A, et al. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res 2003;63:7591-7594. (Pubitemid 37466678)
5. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996;1299:125-140. (Pubitemid 26007741)
6. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12: 1063-1073. (Pubitemid 28418937)
7. Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998;58: 1208-1216. (Pubitemid 28183210)
8. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001. (Pubitemid 28521147)
9. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89:2637-2645. (Pubitemid 32011609)
10. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7: 861-867. (Pubitemid 32708722)
11. Dohadwala M, Luo J, Zhu L, et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 2001;276: 20809-20812.
12. Krysan K, Merchant FH, Zhu L, et al. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J 2004;18:206-208.
13. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921. (Pubitemid 27353455)
14. Fortugno P, Wall NR, Giodini A, et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002;115:575-585. (Pubitemid 34182984)
15. Rodriguez JA, Span SW, Ferreira CG, et al. CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp Cell Res 2002;275:44-53.
16. Weis K. Regulating access to the genome: nucleocytoplasmic transport throughout the cell cycle. Cell 2003; 112:441-451. (Pubitemid 36263078)
17. Rodriguez JA, Lens SM, Span SW, et al. Subcellular localization and nucleocytoplasmic transport of the chromosomal passenger proteins before nuclear envelope breakdown. Oncogene 2006;25: 4867-4879. (Pubitemid 44201178)
18. Knauer SK, Bier C, Habtemichael N, et al. The Survivin-Crm1 interaction is essential for chromosomal passenger complex localization and function. EMBO Rep 2006;7:1259-1265. (Pubitemid 44835095)
19. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-584. (Pubitemid 28563719)
20. Reed JC. The Survivin saga goes in vivo. J Clin Invest 2001;108:965-969. (Pubitemid 32946070)
21. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin Ther Targets 2008;12: 463-476. (Pubitemid 351551639)
22. Krysan K, Dalwadi H, Sharma S, et al. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res 2004;64:6359-6362. (Pubitemid 39297884)
23. Falleni M, Pellegrini C, Marchetti A, et al. Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 2003;200:620-626. (Pubitemid 36987311)
24. Vischioni B, van der Valk P, Span SW, et al. Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. Ann Oncol 2004;15:1654-1660. (Pubitemid 39562606)
25. Lu B, Gonzalez A, Massion PP, et al. Nuclear survivin as a biomarker for non-small-cell lung cancer. Br J Cancer 2004;91:537-540. (Pubitemid 39093575)
26. Kren L, Brazdil J, Hermanova M, et al. Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol 2004;12:44-49. (Pubitemid 38332319)
27. Shinohara ET, Gonzalez A, Massion PP, et al. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer 2005;103:1685-1692. (Pubitemid 40490030)
28. Atikcan S, Unsal E, Demirag F, et al. Correlation between survivin expression and prognosis in nonsmall cell lung cancer. Respir Med 2006;100: 2220-2226. (Pubitemid 44718389)
29. Ulukus EC, Kargi HA, Sis B, et al. Survivin expression in non-small-cell lung carcinomas: correlation with apoptosis and other apoptosis-related proteins, clinicopathologic prognostic factors and prognosis. Appl Immunohistochem Mol Morphol 2007;15: 31-37. (Pubitemid 46673313)
30. Bria E, Visca P, Novelli F, et al. Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer. Eur J Surg Oncol 2008;34:593-598. (Pubitemid 351514886)
31. He L, Hou M, Zhang J, et al. Subcellular localization of survivin in non-small cell lung cancer]. Chinese J Cancer 2009;28:955-960.
32. Travis WD, World Health Organization, International Agency for Research on Cancer, International Association for the Study of Lung Cancer, International Academy of Pathology. Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press: Lyon, 2004.
33. Edge SB, American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Manual 7th edn, Springer: New York, 2010.
34. Xiao J, Tan Y, Pan Y, et al. A new cyclooxygenase-2 inhibitor, (1E,4E)-1,5-bis(2-bromophenyl)penta-1, 4-dien-3-one (GL63) suppresses cyclooxygenase-2 gene expression in human lung epithelial cancer cells: coupled mRNA stabilization and posttranscriptional inhibition. Biol Pharm Bull 2010;33:1170-1175.
35. Sengupta S, Jang BC, Wu MT, et al. The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. J Biol Chem 2003;278:25227-25233. (Pubitemid 37548687)
36. Denkert C, Weichert W, Pest S, et al. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res 2004;64:189-195. (Pubitemid 38114097)
37. Denkert C, Weichert W, Winzer KJ, et al. Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res 2004;10:5580-5586. (Pubitemid 39100499)
38. Mrena J,Wiksten JP, Thiel A, et al. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res 2005;11: 7362-7368. (Pubitemid 41507695)
39. Denkert C, Koch I, von Keyserlingk N, et al. Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol 2006;19:1261-1269. (Pubitemid 44268197)
40. Turini ME, DuBois RN. Cyclooxygenase-2: a therapeutic target. Annu Rev Med 2002;53:35-57. (Pubitemid 34177870)
41. Sheng H, Shao J, Morrow JD, et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58: 362-366. (Pubitemid 28047080)
42. Mahotka C, Wenzel M, Springer E, et al. SurvivindeltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999;59:6097-6102. (Pubitemid 30035627)
43. Li F, Yang J, Ramnath N, et al. Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 2005;114:509-512. (Pubitemid 40349608)
44. Knauer SK, Kramer OH, Knosel T, et al. Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J 2007;21:207-216. (Pubitemid 46052558)
45. Engels K, Knauer SK, Metzler D, et al. Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol 2007;211:532-540. (Pubitemid 46502429)
46. Vischioni B, Oudejans JJ, Kruyt FA, et al. Immunohistochemical detection of nuclear survivin in NSCLC: a comparison of commercial antibodies. Histopathology 2007;50:671-675. (Pubitemid 46495816)